Rhythm Biosciences Yönetim

Yönetim kriter kontrolleri 1/4

Rhythm Biosciences CEO'su David Atkins, May2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı A$ 409.24K olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.1% maaş ve 87.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.61% ine doğrudan sahiptir ve bu hisseler A$ 520.00K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1 yıl ve 1.8 yıldır.

Anahtar bilgiler

David Atkins

İcra Kurulu Başkanı

AU$409.2k

Toplam tazminat

CEO maaş yüzdesi	12.1%
CEO görev süresi	less than a year
CEO sahipliği	1.6%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.8yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03

CEO Tazminat Analizi

David Atkins'un ücretlendirmesi Rhythm Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$409k	AU$49k	-AU$7m

Tazminat ve Piyasa: David 'ın toplam tazminatı ($USD 265.95K ) Australian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 297.98K ).

Tazminat ve Kazançlar: David şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

David Atkins (59 yo)

less than a year

Görev süresi

AU$409,243

Tazminat

Dr. David Atkins, MBA, Ph. D., serves as Chief Executive Officer of Rhythm Biosciences Limited since May 13, 2024 and serves as its Managing Director and Director since September 30, 2024. He was Director...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Atkins	CEO, MD & Director	less than a year	AU$409.24k	1.61% A$ 520.0k
Guy Carisbrooke	Financial Controller	1.2yrs	AU$178.96k	Veri yok
Andrea Steele	General Counsel & Joint Company Secretary	2.8yrs	Veri yok	Veri yok
James Barrie	Joint Company Secretary	less than a year	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim: RHY 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Atkins	CEO, MD & Director	less than a year	AU$409.24k	1.61% A$ 520.0k
Otto Buttula	Non-Executive Chairman	5.1yrs	AU$369.11k	14.64% A$ 4.7m
Susan MacLeman	Independent Deputy Chair	1.8yrs	AU$87.74k	Veri yok

1.8yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RHY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Rhythm Biosciences Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Rhythm Biosciences Ltd Appoints Gavin Fox-Smith as Independent Non-Executive Director Effective 2 December 2024

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

Executive Chairman recently bought AU$248k worth of stock

Recent updates

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Rhythm Biosciences Ltd Appoints Gavin Fox-Smith as Independent Non-Executive Director Effective 2 December 2024

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

New major risk - Share price stability

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New minor risk - Shareholder dilution

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

New minor risk - Financial data availability

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Executive Chairman recently bought AU$248k worth of stock

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Less than half of directors are independent

Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022

Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer

Executive Chairman recently sold AU$6.5m worth of stock

Executive Chairman exercised options to buy AU$459k worth of stock.

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers

Less than half of directors are independent

Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ®

Rhythm Biosciences Ltd Announces Executive Changes

Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Non-Executive Director David White has left the company

Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial

Rhythm Biosciences Betters ColoSTAT Results

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

New 90-day high: AU$1.64

Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site

New 90-day high: AU$1.56

Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites

New 90-day high: AU$1.38

New 90-day high: AU$0.88

Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

New 90-day high: AU$0.28

New 90-day high: AU$0.21

Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial

New 90-day high - AU$0.20

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million.

Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş